Trials / Unknown
UnknownNCT03641794
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers
A Phase I Study of DN1406131 in Healthy Adults
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a double blind Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of DN1406131, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and tryptophan 2,3-Dioxygenase 2 (TDO-2) and help the human immune system attack solid tumor cells more effectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DN1406131 | IDO1 and TDO2 inhibitor |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2018-09-07
- Primary completion
- 2019-05-13
- Completion
- 2019-07-31
- First posted
- 2018-08-22
- Last updated
- 2019-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03641794. Inclusion in this directory is not an endorsement.